Peripheral T-cell Lymphoma Market Size in the 7MM is USD 564 million in 2021

The Peripheral T-cell Lymphoma market is expected to rise due to rising incidence and the expected entry of emerging therapies that will expand the market with novel targets.

The peripheral T-cell Lymphoma market report provides current treatment practices, Peripheral T-cell Lymphoma emerging drugs, and Peripheral T-cell Lymphoma market share of the individual therapies, current and forecasted 7MM Peripheral T-cell Lymphoma market size from 2019 to 2032. The report also covers current Peripheral T-cell Lymphoma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Peripheral T-cell Lymphoma Market Research Report

• The total Peripheral T-cell Lymphoma market size in the 7MM is USD 564 million in 2021 and is projected to grow during the forecast period (2022-2032).

• The total incident population of Peripheral T-cell Lymphoma in the 7MM comprised of 18,027 cases in 2021 and are projected to increase during the forecast period.

• The total Peripheral T-cell Lymphoma market size in the United States is expected to increase with a CAGR of 4.9% during the study period (2019-2032).

• The leading Peripheral T-cell Lymphoma Companies include Eisai, Celgene Corporation, HUYA Bioscience International/Quintiles, Verastem, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, Aileron Therapeutics, Incyte, Novartis, and others.

• Promising Peripheral T-cell Lymphoma Pipeline Therapies include Beleodaq (Belinostat, Acrotech Biopharma); Istodax (Romidepsin), Folotyn (Pralatrexate, Acrotech Biopharma), Arranon (Nelarabine, GlaxoSmithKline), and Adcetris (Brentuximab vedotin, Seattle Genetics), and others.

For more insights into the Peripheral T-cell Lymphoma Market Landscape, visit Peripheral T-cell Lymphoma Market Therapeutics Landscape @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral T-cell Lymphoma Overview
Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called "T cells" and "natural killer (NK) cells." It is PTCL's origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term "peripheral" does not refer to the extremities, but identifies PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin.

Peripheral T-cell Lymphoma Epidemiology Segmentation in the 7MM

• Total Peripheral T-cell Lymphoma Incident Cases

• Peripheral T-cell Lymphoma Stage-Specific Incident Cases (Stage I, Stage II, Stage III, and Stage IV)

• Peripheral T-cell Lymphoma Subtype-Specific Incident Cases (PTCL-NOS, ALCL, AITL, nasal NK/T-cell lymphoma, enteropathy-type intestinal TCL, hepatosplenic TCL, and others)

To know more information of the Peripheral T-cell Lymphoma Epidemiology Segmentation of the report, click here for Peripheral T-cell Lymphoma Epidemiology Insights @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral T-cell Lymphoma Treatment Market
Currently, the Peripheral T-cell Lymphoma market holds treatment options that are supportive in nature, such as conservative (nonsurgical) and surgical methods. Conservative Peripheral T-Cell Lymphoma treatment further includes physical therapy, behavioural therapies, or pharmacological therapies. There are only five FDA permitted products for the treatment of PTCL, are Beleodaq (Belinostat, Acrotech Biopharma); Istodax (Romidepsin, Celgene), Folotyn (Pralatrexate, Acrotech Biopharma), Arranon (Nelarabine, GlaxoSmithKline), and Adcetris (Brentuximab vedotin, Seattle Genetics). The approved PTCL treatment options in the EU are Adcetris (brentuximab vedotin) and Arranon (nelarabine). Adcetris is an antibody-drug conjugate (ADC) that targets CD30. In Europe, the rejection of the approval for Folotyn (pralatrexate) and Istodax (romidepsin) by The European Medicines Agency (EMA) has affected the Peripheral T-cell Lymphoma market scenario to a large extent. As these products showed a lack of evidence in the clinical benefit, they were withdrawn from the market subsequently. Apart from these, Beleodaq (Belinostat) is not licensed in Europe, although the EMA has granted it orphan designation status.

Peripheral T-cell Lymphoma Companies and Pipeline Therapies
• Denileukin diftitox: Eisai
• SP-02 (Darinaparsin, ZIO-101): Solasia Pharma
• Fenretinide (4-HPR): CerRx
• Tipifarnib: Kura Oncology
• HBI-8000: HUYA Bioscience International/Quintiles, Inc.
• COPIKTRA (Duvelisib): Verastem
• Genolimzumab (GB226): Genor Biopharma
• Azacitidine (CC-486): Celgene Corporation
• Tislelizumab: BeiGene
• Lacutamab/IPH4102: Innate Pharma
• AFM13: Affimed GmbH
• Opdivo (nivolumab) + Cabiralizumab: Bristol-Myers Squibb
• Bavencio (avelumab): Pfizer
• Keytruda (pembrolizumab): Merck Sharp & Dohme Corp.
• STI-3031/IMC-001: Sorrento Therapeutics
• ALRN 6924: Aileron Therapeutics
• Masitinib: AB Science
• Ruxolitinib: Incyte Corporation/Novartis
• Aplidin (plitidepsin): PharmaMar
• ASTX660: Otsuka Pharmaceutical/Astex Pharmaceuticals

Browse More Related Reports of the Peripheral T-cell Lymphoma Market Research Reports, click here for Peripheral T-cell Lymphoma Market Forecast @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Peripheral T-cell Lymphoma Market Report

• Coverage- 7MM

• Study Period- 2019-2032

• Peripheral T-cell Lymphoma Companies- Eisai, Celgene Corporation, HUYA Bioscience International/Quintiles, Verastem, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, Aileron Therapeutics, Incyte, Novartis, and others.

• Peripheral T-cell Lymphoma Pipeline Therapies- Beleodaq (Belinostat, Acrotech Biopharma); Istodax (Romidepsin), Folotyn (Pralatrexate, Acrotech Biopharma), Arranon (Nelarabine, GlaxoSmithKline), and Adcetris (Brentuximab vedotin, Seattle Genetics), and others.

• Peripheral T-cell Lymphoma Market Dynamics: Peripheral T-cell Lymphoma Market Drivers and Barriers

• Peripheral T-cell Lymphoma Market Access and Reimbursement, Unmet Needs

Read the Full Research Report of the Peripheral T-cell Lymphoma Market Forecast Report, click here for Peripheral T-cell Lymphoma Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. SWOT Analysis
6. Epidemiology and Market Forecast Methodology
7. Peripheral T-cell Lymphoma (PTCL) Market Overview at a Glance in the 7MM
8. Disease Background and Overview
9. Treatment and Management of PTCL
10. Peripheral T-cell Lymphoma Treatment Guidelines
11. Epidemiology and Patient Population of 7MM
12. Patient Journey
13. Key Endpoints in PTCL
14. Marketed Peripheral T-cell Lymphoma Drugs
15. Emerging Peripheral T-cell Lymphoma Drugs
16. Peripheral T-cell Lymphoma: 7MM Market Analysis
17. Peripheral T-cell Lymphoma Unmet Needs
18. Peripheral T-cell Lymphoma Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Consult with our Business Expert @ Peripheral T-cell Lymphoma Market Landscape- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.